Science & Research
Dermist's efficacy is grounded in scientific research and clinical validation
IPR-Protected Innovation
Dermist's formulation is protected under IPRs, recognizing the innovative use of extracts and other ingredients for psoriasis treatment.
These IPRs reflects years of dedicated research at Astrel Genome Limited, combining traditional botanical knowledge with modern pharmaceutical science.
Clinical Trial Results
12-Week Clinical Trial
A randomized, controlled study involving 120 participants with mild to moderate plaque psoriasis evaluated Dermist's efficacy and safety over a 12-week period.
85%
Reported visible improvement
72%
Reduction in scaling
68%
Decreased redness
Study Methodology
All clinical trials were conducted according to Good Clinical Practice (GCP) guidelines and received ethics committee approval. Participants were evaluated using standardized assessment tools including:
- PASI (Psoriasis Area and Severity Index)
- DLQI (Dermatology Life Quality Index)
- Visual analog scales for itching and discomfort
Key Research Findings
Anti-Inflammatory Properties
Banana extract significantly reduces inflammatory cytokine production, addressing a root cause of psoriasis symptoms.
Skin Barrier Enhancement
Clinical measurements show improved transepidermal water loss (TEWL) values, indicating strengthened skin barrier function.
Antioxidant Activity
Laboratory analyses confirm potent antioxidant properties that help protect skin cells from oxidative stress.
Safety Profile
Dermatological testing and patch tests confirm excellent tolerability with minimal risk of adverse reactions.
Ongoing Research
Our commitment to scientific excellence doesn't end with Dermist's launch. Astrel Genome Limited continues to:
- Conduct post-market surveillance studies to monitor real-world effectiveness
- Investigate additional applications for our patented formulation
- Collaborate with international research institutions to further validate our findings
- Explore optimization opportunities for enhanced efficacy